Antibodies to Heat-Shock Protein 65 and Neopterin Levels in Patients with Type 1 Diabetes Mellitus

2003 ◽  
Vol 111 (03) ◽  
pp. 127-131 ◽  
Author(s):  
R. Weitgasser ◽  
M. Lechleitner ◽  
T. Koch ◽  
G. Galvan ◽  
J. Mühlmann ◽  
...  
1994 ◽  
Vol 11 (1) ◽  
pp. 66-70 ◽  
Author(s):  
R.Y.M. Tun ◽  
M.D. Smith ◽  
S.S.S. Lo ◽  
G.A.W. Rook ◽  
P. Lydyard ◽  
...  

2017 ◽  
Vol 14 (3) ◽  
pp. 184-190 ◽  
Author(s):  
Lili Shen ◽  
Shiping Lu ◽  
Dongcheng Huang ◽  
Guoliang Li ◽  
Kunfeng Liu ◽  
...  

Recent studies have investigated the potential of type 1 diabetes mellitus–related autoantigens, such as heat shock protein 60, to induce immunological tolerance or to suppress the immune response. A functional 24-residue peptide derived from heat shock protein 60 (P277) has shown anti-type 1 diabetes mellitus potential in experimental animals and in clinical studies, but it also carries a potential atherogenic effect. In this study, we have modified P277 to retain an anti-type 1 diabetes mellitus effect and minimize the atherogenic potential by replacing the P277 B epitope with another diabetes-associated autoantigen, insulinoma antigen-2 (IA-2), to create the fusion peptide IA-2-P2. In streptozotocin-induced diabetic C57BL/6J mice, the IA-2-P2 peptide displayed similar anti-diabetic effects to the control P277 peptide. Also, the IA-2-P2 peptide did not show atherogenic activity in a rabbit model. Our findings indicate the potential of IA-2-P2 as a promising vaccine against type 1 diabetes mellitus.


Renal Failure ◽  
2016 ◽  
Vol 38 (3) ◽  
pp. 404-410 ◽  
Author(s):  
Alev Yilmaz ◽  
Asuman Gedikbasi ◽  
Zeynep Yuruk Yildirim ◽  
Cemile Pehlivanoglu ◽  
Basak Seker ◽  
...  

2020 ◽  
Vol 493 (1) ◽  
pp. 124-127
Author(s):  
E. G. Novoselova ◽  
O. V. Glushkova ◽  
M. O. Khrenov ◽  
S. B. Parfenyuk ◽  
S. M. Lunin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document